GlassScriptPhysician profile
Kenneth D Rothstein
NPI 1790753317
$34,267.05
in general payments reported to CMS, 2019-2025
10 companies · $6,229 in 2025
The $6,229 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,529 · 2020: $1,839 · 2021: $2,320 · 2022: $12K · 2023: $6,072 · 2024: $142 · 2025: $6,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,900 · Honoraria: $3,000 · Food and Beverage: $1,077 · Travel and Lodging: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,900.00 |
| Honoraria | $3,000.00 |
| Food and Beverage | $1,077.03 |
| Travel and Lodging | $466.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17,217.55 | 2021-2023 | |
| Abbvie INC. | $7,315.31 | 2019-2020 | |
| Gilead Sciences, INC. | $5,814.93 | 2020-2025 | Livdelzi |
| Orphalan INC | $3,232.93 | 2023-2025 | Cuvrior |
| Madrigal Pharmaceuticals | $481.70 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $129.15 | 2024 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.21 | 2020-2022 | |
| Janssen Biotech, INC. | $28.05 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $13.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.